DOM

DOM (2,5-dimethoxy-4-methylamphetamine), also known by the street designation STP, is a synthetic substituted amphetamine and phenethylamine psychedelic that functions as a potent, full agonist at the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, with low-nanomolar to sub-micromolar binding affinity at the 5-HT2A subtype (Ki approximately 2 to 507 nM across assay conditions) and functional efficacy of 44 to 132 percent of the maximum serotonin response depending on the expression system and signaling readout. First synthesized by Alexander Shulgin at the Dow Chemical Company research laboratories in 1963 and characterized in controlled human studies by Snyder, Faillace, and Hollister in 1967, DOM occupies a foundational position in the pharmacology of serotonergic psychedelics: it was the compound whose structure-activity and drug discrimination relationships provided the first robust quantitative evidence that 5-HT2 receptor agonism is the primary mechanism of hallucinogenesis, a finding subsequently confirmed by radioligand binding correlations (r = 0.938 between 5-HT2 affinity and drug discrimination ED50) and by receptor-selective antagonist reversal experiments with ketanserin and pirenperone.

DOM is approximately 50 to 150 times more potent than mescaline and approximately 30 to 60 times less potent than lysergic acid diethylamide (LSD) on a weight basis in humans, with a threshold oral dose of approximately 1 mg (racemic), hallucinogenic activity in the 3 to 10 mg range, and a duration of action of 14 to 24 hours at moderate doses. The (R)-enantiomer is approximately twice as potent as the racemic mixture. Pharmacokinetics in humans are incompletely characterized but involve hepatic O-demethylation mediated predominantly by CYP2D6, producing the pharmacologically active metabolites 2-O-desmethyl-DOM and 5-O-desmethyl-DOM, with further demethylation to the catechol metabolite 2,5-DDM-DOM, a structural analog of 6-hydroxydopamine that has been identified as a potent neurotoxin capable of alkylating cellular macromolecules following oxidation to its quinone and iminoquinone forms. Approximately 5 to 20 percent of an administered dose is excreted unchanged in urine.

In contemporary preclinical research, DOM serves three principal roles: as a training drug in the operant drug discrimination paradigm, where it is one of the two canonical hallucinogen discriminative stimuli (alongside LSD) and has generated a structure-activity dataset spanning more than 50 phenethylamine and tryptamine analogs; as an inducer of the head-twitch response in mice, a 5-HT2A-dependent behavioral assay that correlates strongly (r = 0.95) with human hallucinogenic potency; and as a pharmacological tool for probing the interaction of 5-HT2A receptor agonism with other receptor systems including opioid antinociception, dopaminergic locomotor regulation, and the cholinergic anti-inflammatory pathway. Recent investigations have examined DOM in the context of 5-HT2A agonist modulation of opioid reinforcement and choice behavior in nonhuman primates, demonstrating that DOM enhances the antinociceptive but not the reinforcing effects of opioids. The compound is classified as Schedule I under the United States Controlled Substances Act, Schedule I under the United Nations Convention on Psychotropic Substances, and analogous restricted classifications in essentially all jurisdictions with psychoactive substance control legislation. It is available as a certified reference standard and research-grade preparation from forensic and pharmacological chemical suppliers. This monograph reviews the chemistry, stereochemistry, and synthesis of DOM; the receptor pharmacology in molecular and behavioral detail; the limited human pharmacokinetic record; the preclinical pharmacology across drug discrimination, head-twitch, locomotor, and opioid interaction paradigms; the historical clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signal; and a comparative assessment of five serotonergic psychedelic research tools against DOM on five competency standards.